Skip to main content
. 2021 Jan 6;14:2. doi: 10.1186/s13104-020-05417-3

Table 2.

Primary and secondary outcomes of participants enrolled in a randomized controlled trial of a tailored smoking cessation intervention for people with HIV in the Washington, D.C. metro area, from baseline to 30-day follow-up, by treatment group (n = 25)

Control Intervention P-valued
Baseline Follow-up Baseline Follow-up
n (%) n (%) n (%) n (%)
Cessation 5.0 (35.7) 3.0 (27.3) 1.0000
Median (IQR) Median (IQR) Median (IQR) Change p-valuec Median (IQR) Median (IQR) Median (IQR) Change p-valuec
Cigarettes per daya 9.0 (1.0, 15.0) 0.5 (0.0, 3.0) − 0.5 (-15.0,0.0) 0.0586 15.0 (6.0, 20.0) 3.0 (0.0, 10.0) − 10.0 (− 19.0, − 3.0) 0.0020 0.1652
Cigarettes per day among those not quitb 3.0 (1.0, 10.0) 3.0 (1.0, 5.0) 0.0 (0.0,1.0) 0.8125 20.0 (9.0, 25.0) 4.0 (2.0, 11.0) − 13.5 (− 19.5, − 2.5) 0.0156 0.0358
Carbon Monoxide (ppm) 14.0 (10.0, 24.0) 7.0 (4.0,14.0) − 5.0 (− 9.0,4.0) 0.0005 19.5 (11.0, 23.5) 12.5 (11.5, 20.0) − 4.5 (− 9.0, 1.0) 0.0488 0.4172
Self Efficacy (Scale: 0-4) 1.8 (1.0, 2.5) 2.5 (1.5, 3.0) 0.3 (0.0, 1.0) 0.0488 1.0 (0.5, 2.5) 2.0 (2.0, 4.0) 1.0 (− 0.5, 2.0) 0.0117 0.4989

aCigarettes per day in the total sample. All those who quit have a CPD of zero. (n = 25)

bCigarettes per day in those who did not quit. All those who quit excluded. (n = 17)

cSignificant differences tested from baseline to follow-up

dSignificant differences tested between study groups